Katrina Megget
FeatureWho will pay for new antibiotics?
Governments around the world are starting to consider alternative funding models and incentives for antibiotics. Katrina Megget asks if it is enough
BusinessStriving to bolster the antibiotic pipeline before it becomes the next crisis
It’s been almost 10 years since the world was warned of a post-antibiotic apocalypse. Katrina Megget takes a look at the initiatives trying to support antimicrobial R&D
BusinessAntibody–drug conjugates drive growth in oncology
Antibody–drug conjugates are coming of age and pharma is investing, reports Katrina Megget
BusinessPatent applications listing AI as an inventor run into legal problems
Artificial intelligence is increasingly being used to find new chemical compounds and repurpose drugs, but should laws be updated to protect the intellectual property of such discoveries?
BusinessUncovering the sources of contaminated sanitisers
Methanol and 1-propanol could get into hand gels by unintentional or deliberate adulteration
BusinessWhat are the risks of fast-tracking a Covid-19 vaccine?
Condensing timelines from years to months inevitably involves compromises
NewsCovid-19 is forcing pharma to rethink clinical trials
Drug trials have become a casualty of Covid-19, but the pandemic is also prompting change
BusinessNovartis exit from antibiotics a setback for race against resistance
Experts say business models must change to halt big pharma exodus
BusinessSanofi enters M&A bonanza
French drugmaker strengthens rare diseases portfolio with blood disorder purchases
NewsLegal battles stall US biosimilars
Unclear legislation and lack of regulatory guidance means companies are turning to the courts
FeatureThe chemistry in your cuppa
Katrina Megget finds there’s more to tea than just a great brew – it’s also chemically complex
BusinessA match made in medicine
Technology companies have begun to turn their resources towards health research. Is it just hype or can big tech bring something new?
FeatureGPS for your health
Katrina Megget discovers that where we live, work and visit can be linked to our health
BusinessLies and deception see Astellas UK suspended by trade body
Company promoted drugs inappropriately and misled regulators in the resulting investigation
FeatureThe cutting edge of gene editing
The new gene-editing tool Crispr is taking the scientific world by storm, reports Katrina Megget
BusinessCrispr goes commercial
Gene editing technique Crispr has shaken up genomics research and the commercial opportunities couldn’t be more evident
ResearchCrispr conversation starter
Alan Regenberg talks to Katrina Megget about the ethics of gene editing
BusinessFixing the broken antibiotics business model
With rising resistance and doomsday warnings, focus is turning to alternative economic models to boost antibiotic R&D
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?